Avanos Medical Stock (NYSE:AVNS)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$24.63

52W Range

$9.30 - $25.49

50D Avg

$24.82

200D Avg

$15.93

Market Cap

$1.17B

Avg Vol (3M)

$1.63M

Beta

1.57

Div Yield

-

AVNS Company Profile


Avanos Medical, Inc. is a pioneering medical technology enterprise dedicated to furnishing device solutions across a broad international footprint, encompassing North America, Europe, the Middle East, Africa, the Asia Pacific region, and Latin America. Its comprehensive product array targets two primary areas: chronic care and non-opioid pain management. Within chronic care, the company provides digestive health offerings such as Mic-Key enteral feeding tubes, Corpak patient feeding systems, and NeoMed solutions tailored for neonatal and pediatric patients. Its respiratory health segment includes closed airway suction systems and other airway management devices, marketed under prominent brands like Ballard, Microcuff, and Endoclear. For non-opioid pain relief, Avanos offers acute pain solutions, including On-Q and ambIT surgical pain pumps, along with Game Ready cold and compression therapy systems. It also features interventional pain solutions, providing minimally invasive therapies like Coolief for long-term pain alleviation. The company facilitates product access by selling directly to hospitals, various healthcare providers, and end-user facilities, in addition to utilizing third-party wholesale distributors. Originally incorporated in 2014 and known as Halyard Health, Inc., the company officially adopted the name Avanos Medical, Inc. in June 2018 and maintains its headquarters in Alpharetta, Georgia.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

2,227

IPO Date

Oct 21, 2014

Website

AVNS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Corporate Other$30.50M--
Digestive Health-$396.40M$371.60M
Interventional Pain-$167.30M$162.50M

Fiscal year ends in Dec 25 | Currency in USD

AVNS Financial Summary


Dec 25Dec 24Dec 23
Revenue$701.20M$687.80M$673.30M
Operating Income$-61.60M$40.00M$65.00M
Net Income$-67.90M$-392.10M$-61.80M
EBITDA$-30.00M$-345.60M$50.60M
Basic EPS$-1.58$-8.53$-1.33
Diluted EPS$-1.58$-8.53$-1.33

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q4 25Feb 24, 26 | 9:00 AM
Q3 25Nov 05, 25 | 9:00 AM
Q2 25Aug 05, 25 | 9:00 AM

Peer Comparison


TickerCompany
CYHCommunity Health Systems, Inc.
CBLLCeriBell, Inc.
CLPTClearPoint Neuro, Inc.
BVSBioventus Inc.
FDMT4D Molecular Therapeutics, Inc.
BCYCBicycle Therapeutics plc
CTKBCytek Biosciences, Inc.
PACBPacific Biosciences of California, Inc.
LABStandard BioTools Inc.
VREXVarex Imaging Corporation